

Cytarabine

Catalog No: tcsc2177

Available Sizes

Size: 100mg

Size: 500mg

Size: 1g

Specifications

CAS No:

147-94-4

Formula:

 $C_9H_{13}N_3O_5$

Pathway: Cell Cycle/DNA Damage;Autophagy

Target:

Nucleoside Antimetabolite/Analog;Autophagy

Purity / Grade:

Solubility:

DMSO : 17.3 mg/mL (71.13 mM; Need ultrasonic and warming); H2O : 48 mg/mL (197.35 mM; Need ultrasonic)

Alternative Names:

Cytosine β -D-arabinofuranoside;Cytosine Arabinoside;Ara-C

Observed Molecular Weight:

243.22

Product Description

Copyright 2021 Taiclone Biotech Corp.



Cytarabine is an antimetabolic agent and **DNA synthesis** inhibitor with **IC**₅₀ of 16 nM.

IC50 & Target: IC50: 16 nM (DNA synthesis)

In Vitro: Cytarabine is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC₅₀ of 16 nM^[1]. Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μ M, of which 100 μ M shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion^[2].

In Vivo: Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity^[3]. Cytarabine is highly effective against acute leukaemias, which causes the Cytarabine teristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man^[4].



Copyright 2021 Taiclone Biotech Corp.